$GH

Krognes Steve E. sold $1.2M of GH

Krognes Steve E. sold 9,294 shares of Guardant Health, Inc. (GH) at $132.51 ($1.23M total) on 2026-06-04.

Original reporting
SEC EDGAR · Krognes Steve E.
Published Jun 5, 2026, 11:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 5, 2026, 11:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
medium confidence
Mentioned
$GH
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The key trading angle is whether the sale is interpreted as a bearish signal given it was not under a pre-arranged 10b5-1 plan; however, insider sales alone rarely drive sustained repricing without accompanying fundamental news.

02

Market read

A single director sale worth ~$1.23M may slightly pressure sentiment, but there is no new operational/financial catalyst in the filing.

03

What to watch

The article lacks context on prior insider activity frequency, option exercises, tax events, and whether the director retains meaningful exposure post-sale.

Relevance 6/10Novelty 6/10Timing: After SEC Form 4 filing (filed 2026-06-05) for a 2026-06-04 sale

Background

This is an SEC Form 4 insider transaction disclosure for Guardant Health, Inc. (GH).

Company-level read

Ticker impact

$GHNeutralMedium confidence
Context

Guardant Health director Steve E. Krognes sold 9,294 shares in an open-market transaction worth about $1.23M, disclosed via SEC Form 4.

Expected impact

Low near-term impact; any effect is likely sentiment-driven and short-lived.

Evidence & confidence

The filing provides a specific sale price/size and confirms it was not under a pre-arranged 10b5-1 plan, which can increase interpretive sensitivity, but it does not include new company fundamentals.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide development.

None indicated.

None indicated.

Counterpoint

Non-10b5-1 sales can be routine liquidity/portfolio rebalancing and may not reflect negative expectations.

Key entities

  • Guardant Health, Inc.

    Issuer of the SEC Form 4 insider transaction; director sold 9,294 shares at ~$132.51.

  • Steve E. Krognes

    Director who executed the open-market sale; holdings after transaction were 10,222 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GRALMed

This test screens for 50 cancers - but whether Medicare and other health insurers will cover it hinges on FDA approval

Grail's Galleri test, which screens for 50 cancers, is under FDA review for approval. A major study failed to prove it detects later-stage cancers, causing skepticism among doctors. Grail's stock dropped 50% on the news but has since rebounded. FDA approval could lead to insurance coverage and impact competitors like Caris Life Sciences and Guardant Health.

$GHHighAI 9/10

Guardant Health (GH) Lands First FDA Cleared Breast Cancer Liquid Biopsy Role

Guardant Health (GH) received FDA approval for its Guardant360 CDx liquid biopsy as a companion diagnostic for advanced HR-positive, HER2-negative breast cancer. This is the first FDA-approved liquid biopsy for longitudinal ctDNA testing in breast cancer. The approval was supported by clinical trial data showing early detection of ESR1 mutations. The company focuses on precision oncology, using blood and tissue tests to tailor cancer treatments. Investors should monitor the impact on future reve

$GHHighAI 9/10

Guardant Health (GH) Wins FDA Approval For First Liquid Biopsy In Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx, a liquid biopsy test to monitor ctDNA in advanced breast cancer. The test guides treatment decisions before disease progression, targeting about 37,000 eligible patients in the US. This approval may influence oncologist testing habits, payer coverage, and Guardant's competitive position in cancer diagnostics.